Peri-Procedural Management of Direct-Acting Oral Anticoagulants (DOACs) in Transcatheter Miniaturized Leadless Pacemaker Implantation
Rattachement africain : ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Data on peri-operative management of direct-acting oral anticoagulants (DOACs) during transcatheter pacing leadless system (TPS) implantation remain limited. This study aimed to evaluate a standardized DOAC management regime consisting in interruption of a single dose prior to implantation and reinitiation within 6-24 hours; also, patient clinical characteristics associated with this approach were identified. Method Consecutive patients undergoing standard TPS implantation procedure from two Swiss tertiary centers were included. DOAC peri-operative management included the standardized approach (Group 1A) or other different approaches (Group 1B). Results Three hundred and ninety two pts (mean age 81.4±7.3 years, 66.3% male, left ventricular ejection fraction 55.5±9.6%) underwent TPS implantation. Two hundred and eighty two pts (71.9%) were under anticoagulation therapy: 192 pts were treated with DOAC; 90 pts were under vitamin-K antagonist. Patients treated with DOAC less often had structural heart disease, diabetes mellitus, and advanced renal failure. The rate of major peri-procedural complications did not differ between Groups 1A (n=115) and 1B (n=77) (2.6% and 3.8%, p=0.685). Compared to 1B, 1A patients were implanted with TPS for slow ventricular rate atrial fibrillation (AF)(p=0.002), were in better overall clinical status, and were implanted electively (<0.001). Conclusions Standardized peri-procedural DOAC management was more often implemented for elective TPS procedure and did not seem to increase bleeding or thromboembolic adverse events.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Peri-Procedural Management of Direct-Acting Oral Anticoagulants (DOACs) in Transcatheter Miniaturized Leadless Pacemaker Implantation
- Date Crossref
- 30/06/2023
- Éditeur
- MDPI AG
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Ospedale San Giovanni Bellinzona pays non établi dans la noticeÉtablissement de santé
-
University Hospital Zurich pays non établi dans la noticeÉtablissement de santé
-
Istituto Cardiocentro Ticino pays non établi dans la noticeÉtablissement de santé
-
Epatocentro Ticino pays non établi dans la noticeÉtablissement de santé
-
San Giovanni Hospital Service of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Cardiocentro Ticino Institute Cardiology Department pays non établi dans la noticeStructure de recherche
-
Hospital of San Giovanni Service of Cardiology pays non établi dans la noticeÉtablissement de santé
-
University Heart Center Zurich pays non établi dans la noticeUniversité ou école supérieure
Ospedale San Giovanni Bellinzona, University Hospital Zurich et Istituto Cardiocentro Ticino, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.